KEC International Limited (BOM:532714)
India · Delayed Price · Currency is INR 842.15
+8.95 (1.07%)
At close: Aug 5, 2025
Longboard Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Revenue | 223,577 | 218,467 | 199,142 | 172,817 | 137,423 | 131,142 | Upgrade |
Revenue Growth (YoY) | 10.78% | 9.70% | 15.23% | 25.76% | 4.79% | 9.60% | Upgrade |
Cost of Revenue | 170,407 | 166,019 | 153,082 | 133,523 | 102,679 | 94,861 | Upgrade |
Gross Profit | 53,170 | 52,448 | 46,060 | 39,295 | 34,744 | 36,281 | Upgrade |
Selling, General & Admin | 19,479 | 19,250 | 17,837 | 16,820 | 14,936 | 12,743 | Upgrade |
Other Operating Expenses | 17,897 | 18,200 | 16,110 | 14,449 | 11,377 | 12,230 | Upgrade |
Operating Expenses | 39,206 | 39,287 | 35,800 | 32,884 | 27,891 | 26,499 | Upgrade |
Operating Income | 13,964 | 13,160 | 10,260 | 6,410 | 6,853 | 9,782 | Upgrade |
Interest Expense | -6,494 | -6,532 | -6,500 | -5,340 | -3,107 | -2,574 | Upgrade |
Interest & Investment Income | 552.4 | 552.4 | 453.2 | 232 | 105.6 | 47.4 | Upgrade |
Currency Exchange Gain (Loss) | 75.1 | 75.1 | 58.9 | 281.9 | 610.2 | 113.7 | Upgrade |
Other Non Operating Income (Expenses) | -410.8 | -33.4 | -13.3 | -7.1 | -32.8 | 117.4 | Upgrade |
EBT Excluding Unusual Items | 7,687 | 7,223 | 4,259 | 1,577 | 4,429 | 7,486 | Upgrade |
Gain (Loss) on Sale of Assets | 85.6 | 85.6 | 32.6 | 42.8 | 8.6 | 81.5 | Upgrade |
Asset Writedown | -33.2 | -33.2 | -26.4 | -9.5 | -6.7 | -8.6 | Upgrade |
Other Unusual Items | - | - | - | - | -436.4 | - | Upgrade |
Pretax Income | 7,740 | 7,275 | 4,265 | 1,610 | 3,994 | 7,559 | Upgrade |
Income Tax Expense | 1,662 | 1,568 | 797.1 | -150.5 | 673.5 | 2,032 | Upgrade |
Earnings From Continuing Operations | 6,078 | 5,707 | 3,468 | 1,760 | 3,321 | 5,527 | Upgrade |
Net Income | 6,078 | 5,707 | 3,468 | 1,760 | 3,321 | 5,527 | Upgrade |
Net Income to Common | 6,078 | 5,707 | 3,468 | 1,760 | 3,321 | 5,527 | Upgrade |
Net Income Growth | 55.03% | 64.58% | 97.00% | -46.99% | -39.92% | -2.26% | Upgrade |
Shares Outstanding (Basic) | 264 | 262 | 257 | 257 | 257 | 257 | Upgrade |
Shares Outstanding (Diluted) | 264 | 262 | 257 | 257 | 257 | 257 | Upgrade |
Shares Change (YoY) | 2.71% | 1.82% | - | - | - | - | Upgrade |
EPS (Basic) | 23.01 | 21.80 | 13.49 | 6.85 | 12.92 | 21.50 | Upgrade |
EPS (Diluted) | 23.01 | 21.80 | 13.49 | 6.85 | 12.92 | 21.50 | Upgrade |
EPS Growth | 50.91% | 61.62% | 97.00% | -46.99% | -39.92% | -2.26% | Upgrade |
Free Cash Flow | - | 2,366 | 737.7 | 4,355 | -4,269 | 6,595 | Upgrade |
Free Cash Flow Per Share | - | 9.04 | 2.87 | 16.94 | -16.60 | 25.65 | Upgrade |
Dividend Per Share | - | 5.500 | 4.000 | 3.000 | 4.000 | 4.000 | Upgrade |
Dividend Growth | - | 37.50% | 33.33% | -25.00% | - | 17.65% | Upgrade |
Gross Margin | 23.78% | 24.01% | 23.13% | 22.74% | 25.28% | 27.66% | Upgrade |
Operating Margin | 6.25% | 6.02% | 5.15% | 3.71% | 4.99% | 7.46% | Upgrade |
Profit Margin | 2.72% | 2.61% | 1.74% | 1.02% | 2.42% | 4.21% | Upgrade |
Free Cash Flow Margin | - | 1.08% | 0.37% | 2.52% | -3.11% | 5.03% | Upgrade |
EBITDA | 15,399 | 14,628 | 11,859 | 7,768 | 8,041 | 10,897 | Upgrade |
EBITDA Margin | 6.89% | 6.70% | 5.96% | 4.50% | 5.85% | 8.31% | Upgrade |
D&A For EBITDA | 1,435 | 1,468 | 1,599 | 1,358 | 1,189 | 1,115 | Upgrade |
EBIT | 13,964 | 13,160 | 10,260 | 6,410 | 6,853 | 9,782 | Upgrade |
EBIT Margin | 6.25% | 6.02% | 5.15% | 3.71% | 4.99% | 7.46% | Upgrade |
Effective Tax Rate | 21.47% | 21.55% | 18.69% | - | 16.86% | 26.88% | Upgrade |
Revenue as Reported | 223,908 | 219,176 | 199,666 | 173,130 | 137,557 | 131,441 | Upgrade |
Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.